Libra Therapeutics is focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases.
Location: United States, California, San Diego
Total raised: $29M
Investors 2
| Date | Name | Website |
| 06.12.2020 | Dolby Fami... | dolbyventu... |
| - | Epidarex C... | epidarex.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.09.2020 | Series A | $29M | - |
Mentions in press and media 6
| Date | Title | Description |
| 29.09.2020 | Libra Therapeutics Raises $29M | Libra Therapeutics, a biotechnology company focused on developing novel disease-modifying therapeutics, has officially launched with $29 million in Series A financing to restore the cellular balance lost in neurodegenerative diseases... Tak... |
| 23.09.2020 | Libra Therapeutics Launches with $29 Million Series A | SAN DIEGO--(BUSINESS WIRE)--Libra Therapeutics, Inc. launched today to develop novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases. These include amyotrophic lateral sclerosis (ALS) and frontot... |
| 23.09.2020 | Libra Therapeutics has raised a $29M Series A round to develop treatments against toxic proteins that damage nerves | - |
| 23.09.2020 | Libra Therapeutics Raises $29M in Series A Funding | Libra Therapeutics, Inc., a San Diego, CA-based developer of novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases, secured $29m in Series A financing. The round was co-led by Boehringer Ingelhei... |
| 23.09.2020 | Libra Therapeutics Nabs $29M For Neurodegenerative Disease Treatments | San Diego-based Libra Therapeutics, a new startup developing treatments for various neurodegenerative diseases, has raised $29M in its Series A funding round, the company said this morning. According to Libra Therapeutics, the funding was c... |
| 23.09.2020 | Libra Therapeutics Launches with $29M Series A | SAN DIEGO, CA, Libra Therapeutics has secured $29 million in Series A financing co-led by Boehringer Ingelheim Venture Fund, Epidarex Capital, and Sante. >> Click here for more funding data on Libra Therapeutics >> To export... |